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Global analysis
Normalization using fold-change dataEmergence of inﬂuenza viruses with reduced susceptibility to neuraminidase inhibitors (NAIs) is spo-
radic, often follows exposure to NAIs, but occasionally occurs in the absence of NAI pressure. The emer-
gence and global spread in 2007/2008 of A(H1N1) inﬂuenza viruses showing clinical resistance to
oseltamivir due to neuraminidase (NA) H275Y substitution, in the absence of drug pressure, warrants
continued vigilance and monitoring for similar viruses. Four World Health Organization (WHO) Collabo-
rating Centres for Reference and Research on Inﬂuenza and one WHO Collaborating Centre for the Sur-
veillance, Epidemiology and Control of Inﬂuenza (WHO CCs) tested 11,387 viruses collected by WHO-
recognized National Inﬂuenza Centres (NIC) between May 2012 and May 2013 to determine 50% inhib-
itory concentration (IC50) data for oseltamivir, zanamivir, peramivir and laninamivir. The data were eval-
uated using normalized IC50 fold-changes rather than raw IC50 data. Nearly 90% of the 11,387 viruses
were from three WHO regions: Western Paciﬁc, the Americas and Europe. Only 0.2% (n = 27) showed
highly reduced inhibition (HRI) against at least one of the four NAIs, usually oseltamivir, while 0.3%
(n = 39) showed reduced inhibition (RI). NA sequence data, available from the WHO CCs and from
sequence databases (n = 3661), were screened for amino acid substitutions associated with reducedcreening
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ptibility.
32 A. Meijer et al. / Antiviral Research 110 (2014) 31–41NAI susceptibility. Those showing HRI were A(H1N1)pdm09 with NA H275Y (n = 18), A(H3N2) with NA
E119V (n = 3) or NA R292K (n = 1) and B/Victoria-lineage with NA H273Y (n = 2); amino acid position
numbering is A subtype and B type speciﬁc. Overall, approximately 99% of circulating viruses tested dur-
ing the 2012–2013 period were sensitive to all four NAIs. Consequently, these drugs remain an appropri-
ate choice for the treatment and prophylaxis of inﬂuenza virus infections.
 2014 The Authors. Published by Elsevier B.V. This is anopenaccess article under the CCBY license (http://
creativecommons.org/licenses/by/3.0/).1. Introduction
Neuraminidase inhibitors (NAIs) are the most widely used anti-
viral drugs for the treatment or prophylaxis of inﬂuenza. The older
class of inﬂuenza antivirals, the adamantanes, are currently not
recommended for use due to the high frequency (>99%) of resis-
tance in circulating inﬂuenza A viruses [A(H1N1)pdm09 and
A(H3N2)] and their ineffectiveness against inﬂuenza B viruses
(Simonsen et al., 2007; Nelson et al., 2009; Tisdale, 2009;
Gubareva et al., 2010). The NAIs oseltamivir and zanamivir have
been approved for use in many countries since 1999/2000, while
two other NAIs, peramivir and laninamivir, have to date been
approved in Japan, and in the case of peramivir also in the Republic
of Korea and China.
The NAIs bind to the neuraminidase (NA) glycoprotein on the
surface of inﬂuenza A and B viruses, restricting the capacity of these
viruses to release from host cells, a critical stage of virus replication.
Substitutions of amino acids located in or close to the NA active site
can lead to reductions in NAI binding and effectiveness of drug
treatment. Such viruses are typically described as being ‘resistant’
to or showing ‘reduced inhibition’ or ‘highly reduced inhibition’
by particular NAIs; these terms might be confusing, as ‘resistant’
relates to clinical effectiveness and ‘reduced inhibition/highly
reduced inhibition’ to the biological characteristics of the NA.
Therefore clear deﬁnitions were formulated by the World Health
Organization (WHO) Global Inﬂuenza Surveillance and Response
System (GISRS) expert working group on surveillance of inﬂuenza
antiviral susceptibility (WHO-AVWG) using 50% inhibitory concen-
tration (IC50; the concentration of drug required to inhibit a stand-
ardised amount of NA activity by 50%) fold-change thresholds,
compared to the mean or median for viruses from the same type/
subtype/lineage showing ‘normal inhibition’ (NI), for reporting
and classifying the NAI susceptibility of viruses to individual NAIs
(WHO, 2012). The rationale for the selection of speciﬁc fold-change
values is described in detail in a previous report (WHO, 2012).
Those showing ‘reduced inhibition’ (RI) are inﬂuenza A viruses that
have a 10- to 100-fold increase in IC50, or inﬂuenza B viruses with a
5- to 50-fold increase in IC50. Viruses showing ‘highly reduced inhi-
bition’ (HRI) are inﬂuenza A viruses with a >100-fold increase in
IC50 or inﬂuenza B viruses with a >50-fold increase in IC50 (WHO,
2012). Infections with viruses showing HRI are considered ‘clini-
cally resistant’ if treatment with the antiviral drug for which the
virus shows HRI has reduced clinical effectiveness.
In most years the frequency of circulating inﬂuenza viruses
showing RI or HRI is less than 1%, but occasionally inﬂuenza
viruses with RI or HRI spread widely within a community (Hurt
et al., 2011; Garg et al., 2013). The most extreme example was in
2007/2008, when the former seasonal A(H1N1) virus acquired
the NA H275Y substitution and spread globally in approximately
12 months (Lackenby et al., 2008; Collins et al., 2009; Dharan
et al., 2009; García et al., 2009; Hauge et al., 2009; Hurt et al.,
2009; Meijer et al., 2009). This NA substitution conferred HRI by
both oseltamivir and peramivir, and was shown in clinical situa-
tions to render oseltamivir, the most widely used NAI, signiﬁcantly
less effective for the treatment of this virus infection (Kawai et al.,
2009; Dharan et al., 2010). Amino acid substitutions D344N andR222Q in the NA of former seasonal A(H1N1) compensated for
the detrimental effect of the HRI H275Y substitution on virus ﬁt-
ness, allowing the virus to spread efﬁciently (Abed et al., 2011;
Rameix-Welti et al., 2011). As regional differences in NAI use exist,
high use in Japan and the United States of America (USA) and low
use in other parts of the world, this could potentially bias the
results in a given region if post treatment reduced susceptibility
is prevalent and a substantial proportion of such viruses are sub-
mitted to the WHO CC. However, to date such regional differences
have not been observed.
On an annual basis, the WHO convenes a technical consultation,
the WHO-AVWG, comprised of representatives from the WHO Col-
laborating Centres for Reference and Research on Inﬂuenza (WHO
CCs), a selection of WHO-recognized National Inﬂuenza Centres
(NICs) and public health institutes and research laboratories with
expertise in inﬂuenza antiviral susceptibility surveillance (WHO,
2012, 2013). The meeting of the WHO-AVWG provides an opportu-
nity to analyse the NAI susceptibility data for inﬂuenza viruses
collected across 126 countries by GISRS laboratories over the pre-
vious 12 months. In this paper, which is the ﬁrst of a series of
annual reports, we present the results for viruses collected via
GISRS and analysed by ﬁve WHO CCs between May 2012 and
May 2013 (subsequently referred to as 2012–2013).2. Overall analysis of phenotypic antiviral susceptibility data
from WHO CCs
Five WHO CCs (Atlanta, United States; Beijing, China; London,
United Kingdom; Melbourne, Australia; and Tokyo, Japan; http://
www.who.int/inﬂuenza/gisrs_laboratory/collaborating_centres/
list/en/). provided IC50 and NA amino acid substitution data for
virus isolates, notably for those showing RI or HRI by NAIs, with
specimen collection dates between week 21/2012 (19/5/2012)
through week 20/2013 (19/5/2013) inclusive. Epidemiologic data
for patient gender, age, geographic location, setting (community,
hospitalised and sentinel/non-sentinel specimen collection), anti-
viral treatment history and immune status were also included in
the analyses when available. All ﬁve WHO CCs tested for oseltam-
ivir and zanamivir susceptibility, and additionally the Atlanta, Mel-
bourne and Tokyo WHO CCs tested for peramivir and laninamivir
susceptibility.
The WHO CCs tested 11,387 viruses, collected during the 2012–
2013 period, for NAI susceptibility using local implementations of
the ﬂuorescence-based neuraminidase inhibition assay described
by Potier et al., 1979. The viruses rescued are mostly derived from
community surveillance specimens collected at ﬁrst encounter of
the patient, so they are unlikely to have been treated with NAI. A
small proportion of viruses are likely to be derived from patients
during or after treatment with NAI, but the actual number is
unknown as antiviral treatment information is not available for
many of the specimens submitted to the WHO CCs. The number
tested was well distributed across the time period but with
increased numbers over the periods of epidemics in the Southern
and Northern Hemispheres (Fig. 1A). Across the 12 months there
were 5109 (45%) A(H3N2), 2343 (21%) A(H1N1)pdm09, 2172
A. Meijer et al. / Antiviral Research 110 (2014) 31–41 33(19%) B/Yamagata-lineage and 1763 (15%) B/Victoria-lineage
viruses tested. By WHO region (http://www.who.int/about/struc-
ture/en/), 42% of viruses tested originated from the Western Paciﬁc
Region, 34% from the Americas, 13% from Europe, 6% from Africa,
4% from South-East Asia and 2% from the Eastern Mediterranean
Region (Fig. 1B).
The methodologies used for the phenotypic NA enzyme inhibi-
tion assays in the ﬁve WHO CCs are different, resulting in variation
of IC50 values between the laboratories for a panel of reference
viruses (Table 1) and test viruses (examples in Fig. 2; full details
for each A subtype and B lineage by WHO CC and NAI in Supple-
mentary Fig. 1). In addition, the London WHO CC changed its
equipment halfway through the study period, so their data for
the two periods were analysed separately.
Comparison of the median (four WHO CCs) and mean (Tokyo
WHO CC) NAI-speciﬁc IC50 values reported by individual WHO
CCs for each virus subtype or lineage revealed sufﬁcient variation
between laboratories to prevent the pooling of raw IC50 data
(Fig. 3). All 16 datasets (4 virus subtypes or lineages and 4 NAIs)
showed signiﬁcant differences (p < 0.05) between WHO CCs by
one-way ANOVA Kruskal–Wallis test of the median of log-
transformed IC50 values (Supplementary Table 1). By pairwise0 
50
100
150
200
250
300
350
400
20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44
2012
N
um
be
r o
f v
iru
se
s
Year and week 
A 
0 
1000
2000
3000
4000
5000
Af
ric
a
Ea
st
er
n 
M
ed
ite
rra
ne
an
Eu
ro
pe
So
ut
h-
Ea
st
 A
si
a
Am
er
ic
as
W
es
te
rn
 P
ac
ifi
c
Af
ric
a
Ea
st
er
n 
M
ed
ite
rra
ne
an
Eu
ro
pe
So
ut
h -
Ea
st
 A
si
a
Am
er
ic
as
Oseltamivir Zanamivir
N
um
be
r o
f v
iru
se
s
A(H1N1)pdm09 A
B 
Fig. 1. Inﬂuenza viruses collected and tested for NAI susceptibility during 2012–2013. (
two peaks in specimen collection, during the Southern Hemisphere winter in week 28, 2
tested for susceptibility to the four NAIs by WHO region. The greatest number of viruses t
for susceptibility to oseltamivir and zanamivir and a high proportion against peramivircomparison of the log-transformed IC50 values, 125 of the 144
comparisons appeared to be statistically different (Dunn’s multiple
comparison test; p < 0.05) (Supplementary Table 1). As an alterna-
tive to using raw IC50 data, a fold-change in IC50 was determined
for each test virus compared to the median (four WHO CCs) or
mean (Tokyo WHO CC) NAI-speciﬁc IC50 values reported by indi-
vidual WHO CCs for each virus subtype or lineage. By using this
conversion of all raw IC50 data into relative fold-change values,
the distributions could be normalized, thereby allowing a pooled
analysis of the data from all ﬁve WHO CCs (examples in Fig. 2; full
details for each A subtype and B lineage by WHO CC and NAI in
Supplementary Fig. 1). By pairwise comparison, the percentage sta-
tistically different comparisons reduced from 87% (125/144) with
raw IC50 data to 8% (11/144) with fold-change data (Supplemen-
tary Table 1). In addition, the level of signiﬁcance was less strong
with fold-change data (median signiﬁcant p-value 0.0026; range
<0.0001–0.0312) than with the raw IC50 data (median signiﬁcant
p-value <0.0001; range <0.0001–0.0461).
IC50 fold-change graphs were constructed based on log-trans-
formed IC50 fold-change data utilizing a box-and-whisker plot
analysis using Tukey’s method to display the range of data and
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34 A. Meijer et al. / Antiviral Research 110 (2014) 31–41constructed with the Y-axis split into three sections indicating the
IC50 fold-change range for viruses classiﬁed as NI, RI or HRI based
on the criteria above (Fig. 4). Among 11,387 viruses tested, 66
viruses (0.6%) showed RI or HRI to one or more of the NAIs
(Fig. 4 and Table 2). The NA genes from 38 of these viruses were
sequenced, with 35 of them encoding an amino-acid substitution
in the NA compared to wild type viruses showing NI (Table 2).3. A(H1N1)pdm09 viruses showing RI or HRI
Twenty two A(H1N1)pdm09 viruses out of 2343 tested (1%)
showed RI or HRI by one or more of the NAIs (Fig. 4; Table 2).
The most commonly detected NA amino acid substitution was
H275Y, present in 18 viruses showing RI or HRI by oseltamivir
(22 viruses tested) and peramivir (13 viruses tested). Of the 18
H275Y variants, six were from the Western Paciﬁc, six from the
Americas, ﬁve from Europe and one from South-East Asia, from
11 countries in total. The H275Y substitution conferred 207- to
4010-fold higher oseltamivir IC50 values and 157- to 1672-fold
higher peramivir IC50 values compared to wild type viruses, but
had little or no effect on zanamivir or laninamivir susceptibility
(Table 2). Of the nine clinical specimens for which sequence results
were available, all contained the H275Y substitution. Because for-
mer seasonal A(H1N1) viruses possessing NA H275Y substitution
spread globally in 2008 (Lackenby et al., 2008; Collins et al.,
2009; Dharan et al., 2009; García et al., 2009; Hauge et al., 2009;
Hurt et al., 2009; Meijer et al., 2009), and a cluster of
A(H1N1)pdm09 viruses with NA H275Y substitution was detected
in untreated community cases in Australia in 2011 (Hurt et al.,
2011), there has been signiﬁcant concern that such variant viruses,
with HRI, may acquire the ability to spread widely.
Of the H275Y variant viruses detected in 2012–2013 where
patient setting and antiviral treatment information was available,
80% were from non-hospitalised patients that had not been treated
with oseltamivir, suggesting that there is potential for spontaneous
emergence and spread of these resistant viruses in the community.
In addition, all ﬁve patients for whom immune status information
was available were reported as not being immunocompromised.
NA amino acid substitutions D151E, Q136K and Q136R were
detected, once each, in viruses with altered NAI susceptibility,
but such substitutions can emerge during MDCK cell culture
(Okomo-Adhiambo et al., 2010). The clinical specimens yielding
two of these isolates were unavailable, but the specimen yielding
the Q136R isolate did not contain the mutation conferring the
amino acid substitution prior to cell culture. As the IC50 data reﬂect
the ﬁndings for virus isolates tested by the WHO CCs, these viruses
were included in the total count of viruses showing RI or HRI. One
A(H1N1)pdm09 virus isolate from Argentina, A/Salta/1341/2012,
contained a N295S amino acid substitution which conferred HRI
by oseltamivir but had only a mild effect on zanamivir susceptibil-
ity. The NA N295S substitution was subsequently conﬁrmed in the
clinical specimen from which A/Salta/1341/2012 was isolated. This
NA N295S substitution has been reported previously in clinical
specimens (Morlighem et al., 2011).4. A(H3N2) viruses showing RI or HRI
Twenty one A(H3N2) viruses out of 5109 tested (0.4%) showed
RI or HRI by one or more of the NAIs (Fig. 4; Table 2). The most
commonly detected NA amino acid substitution was E119V, pres-
ent in three of the ﬁve viruses for which sequences were available
(Table 2), two from the Americas and one from the Western Paciﬁc.
The E119V substitution conferred increases in oseltamivir IC50 val-
ues ranging from 120- to 454-fold compared to that of A(H3N2)
viruses showing NI, while retaining NI by zanamivir, laninamivir
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A. Meijer et al. / Antiviral Research 110 (2014) 31–41 35and peramivir. Although treatment information was unavailable
for one of the cases, two of the E119V variant viruses came from
patients undergoing oseltamivir treatment. An A(H3N2) virus with
a R292K NA substitution was also recovered from an oseltamivir-
treated patient. This virus showed a >60,000-fold increase in osel-
tamivir IC50, a 474-fold increase in peramivir IC50 and a 53-fold
increase in zanamivir IC50 compared to values for A(H3N2) viruses
displaying NI by the three NAIs (Table 2). The E119V and R292K
substitutions were also detected in the corresponding clinical spec-
imens. The remaining 17 A(H3N2) viruses had IC50 values that
were around the intersect between NI and RI categories, and were
either not sequenced or sequenced but with no NA amino acid sub-
stitutions being detected (Table 2).5. B/Victoria-lineage viruses showing RI or HRI
Seventeen B/Victoria-lineage viruses out of 1763 tested (1%)
showed RI or HRI by one or more of the NAIs (Fig. 4; Table 2);
of 16 of these viruses tested against peramivir, 15 showed RI or
HRI and 13 of these 15 showed NI to the other three NAIs. Two
viruses from epidemiologically related cases in the Western Paci-
ﬁc Region contained NA H273Y substitutions which conferred
210- to 322-fold increases in peramivir IC50 but had no effect
on susceptibility to the other NAIs. All of the isolates that were
classiﬁed as having RI to peramivir require further analysis to
conﬁrm that the NA substitutions identiﬁed in the isolates are
responsible for the changes in IC50. In two cases for which
sequence results for the clinical specimens were available, the
NA substitutions associated with RI or HRI were not found,
further demonstrating the potential for viruses with RI or HRI
to arise during cell culture (Table 2).6. B/Yamagata-lineage viruses showing RI or HRI
Only six B/Yamagata-lineage viruses out of 2172 tested (0.3%)
showed RI by at least one of the NAIs (Fig. 4; Table 2). All six
viruses fell at the intersect between NI and RI (the greatest IC50 fold
increase for these six viruses compared to the median was 7.3-fold)
so although some NA substitutions were detected, further investi-
gation is needed to assess the role of these substitutions in altering
NAI susceptibility.7. Frequency of RI and HRI conferring NA amino acid
substitutions in sequence databases
On the WHO website, the AVWG lists NA amino acid substitu-
tions that (i confer either clinical resistance/HRI (e.g. H275Y) or
HRI/RI in vitro, and (ii have been conﬁrmed to occur in patient clin-
ical specimens (not just virus isolates). The list of amino acid sub-
stitutions is available at: http://www.who.int/inﬂuenza/gisrs_
laboratory/antiviral_susceptibility/nai_overview/en/ (accessed 9
May 2014), and displayed in Tables 3 and 4. This list is reassessed
by the AVWG on an annual basis and updated as required to
include new NA substitutions that confer reduced susceptibility.
For example, the list currently requires the inclusion of the B NA
I221V substitution that was present in a cluster of inﬂuenza B
viruses detected in North and South Carolina, United States of
America, in 2011/2012 (Garg et al., 2013) and the B NA I221L sub-
stitution that emerged in an immunocompromised patient treated
with oseltamivir and yielded viruses showing HRI (Escuret et al.,
2014). However the merits of including substitutions such as
D199N in N1 described below, that confer only a few fold increase
in IC50, and therefore remain classiﬁed as showing NI, requires
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screen NA sequence data for known substitutions that have previ-
ously been shown, via functional assays, to alter (decrease) NAI
susceptibility.
Using the list we screened NA sequences from viruses collected
during the 2012–2013 period that had been deposited on inﬂuenza
sequence databases (Global Initiative on Sharing All Inﬂuenza Data
[GISAID] at www.gisaid.org and National Center for Biotechnology
Information Inﬂuenza Virus Resource [NCBI-IVR] at www.ncbi.nlm.
nih.gov/genomes/FLU/FLU.html).
Following the curation of sequence data to ensure short, dupli-
cate or poor quality sequences were removed, a total of 3661
sequences from GISAID and NCBI-IVR were analysed for the pres-
ence of key NA amino acid substitutions (Supplementary Table 2).
Many of the sequences in the databases were from viruses col-
lected through the GISRS network, and therefore there was signif-
icant overlap between the viruses represented in the databases,
and those characterised via phenotypic analysis in GISRS laborato-
ries; 2826/3661 (77%) of the sequences were deposited by WHO
CCs and were included in the IC50 dataset of the WHO CCs (Tables
3 and 4 and Supplementary Table 3). Twenty-two of the 1083 (2%)
N1 sequences from A(H1N1)pdm09 viruses contained the H275Y
substitution (Table 3), of which 16 had been analysed by NAinhibition assay at one of the WHO CCs and are included in the
viruses shown in Fig. 4A and Table 2. However, there were six
NA H275Y variant viruses from Brazil (n = 3), Sweden (n = 1), India
(n = 1) and Lao People’s Democratic Republic (n = 1) that were
present in the sequence databases that had not been analysed/
reported within the GISRS network and therefore not included in
the WHO CCs IC50 dataset. Including the six NA H275Y viruses
reported in the sequence database only and the two NA H275Y
viruses reported in the WHO CC dataset only (1 from China and
1 from Singapore), the 24 NA H275Y viruses were derived from
14 countries worldwide and specimens collected throughout the
reporting period. No clear clustering was found, although the two
NA H275Y viruses from the Netherlands were associated with pos-
sible transmission at a holiday location (Meijer et al., 2012) and the
four NA H275Y viruses from Brazil were associated with possible
community transmission in the south of the country (Souza
et al., 2013). Of the 1083 N1 sequences 1054 (97%) contained
V241I substitution, and 1050 (97%) N369 K substitution, which
are compensatory for H275Y substitution, thereby increasing the
risk of emergence of ﬁt oseltamivir HRI A(H1N1)pdm09 viruses
that could spread worldwide (Butler et al., 2014).
Analysis of the available sequences also identiﬁed two N1
sequences containing D199N substitution and one inﬂuenza B NA
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Table 2
Virus and patient characteristics of 66 viruses showing RI or HRI, tested by WHO CCs.a
Virus n IC50 fold-change compared to reference median or mean IC50 valuesb NA-substitutionc Patient setting Antiviral treatment Immuno-compromised
Oseltamivir Zanamivir Peramivir Laninamivir Virus isolate Clinical specimen
A(H1N1)pdm09; N = 2343 18 207–4010 1.0–6.5 157–1672 (13) 1.0–5.1 (13) H275Y H275Y (9) Community (8) Hospital (2) Yes, oseltamivir (1)
Yes, not speciﬁed (1)
No (8)
No (5)
1 3.0 19 14 5.0 D151D/E na na na na
1 0.6 200 234 33 Q136R 136Q Community No No
1 0.6 185 143 42 Q136 K na na na na
1 124 9.0 na na N295S N295S Hospital na na
A(H3N2); N = 5109 3 120–454 1.2–5.7 0.9–3.7 1.3–3.0 E119V (1 mixed)d E119V (3 mixed)d Hospital (1) Yes, oseltamivir (1)
Yes, not speciﬁed (1)
Yes (1)
1 67,338 53 474 5.3 R292 K R292 K Hospital Yes, oseltamivir Yes
1 4.6 17 na na None na Community No na
16 2.4–19 0.5–7.5 0.1–14 0.7–4.8 Not sequenced Na Community (2) Hospital (5) na na
B/Victoria- lineage; N = 1763 2 1.7–2.4 0.3–0.4 6.9–8.1 0.6–0.7 E264V Na na na na
2 3.6–3.7 0.6–1.2 210–322 1.2–1.9 H273Y na Community No No
1 1.5 0.9 7.1 0.9 G148G/R, K343Ee na na na na
1 2.9 1.6 6.0 0.9 Y142H 142Y Community na na
1 1.1 0.9 18.7 0.6 V71A, H439R V71A, 439H na na na
1 3.4 5.30 na na None na na na na
9 1.0–5.4 0.4 – 3.3 1.7–11.9 0.6–3.1 Not sequenced na Community (4) Yes, zanamivir (1) No (3)
B/Yamagata- lineage; N = 2172 1 5.0 1.0 na na A55T, H296Y na Community na na
1 7.3 1.0 na na P76S, A358T, E392G na Community na na
1 3.0 5.9 na na None na Community No na
3 2.6–3.3 2.1–5.4 5.4–5.5 (2) 1.7–2.5 (2) Not sequenced na Hospital (2) No (1) na
a Between brackets the number of viruses for which data was reported if less than the number reported in column ‘n’. RI = reduced inhibition; HRI = highly reduced inhibition; na = not available; None = no amino acid
substitutions compared to viruses with NI phenotype.
b RI and HRI fold-change values are displayed underlined and in bold typeface.
c Amino acid position numbering is A subtype and B type speciﬁc.
d One virus isolate and all three clinical specimens showed 119E/V polymorphism.
e Two other B/Victoria/2/87 lineage viruses with K343E only did not show RI with any of the antivirals.
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Table 3
Frequency of amino acid substitutions in inﬂuenza NAs, submitted to GISAID and NCBI sequence databases, known to occur clinically and cause clinical resistance.a
Type/
Subtype
Neuraminidase
amino acid
substitutionb
No. of sequences
containing
the substitution
(%)c
Virus Home country patient Specimen
collection date
Included in phenotypic
analysisd
A(N1) H275Y 22 (2%) A/Austria/713625/2013 Austria 8-1-2013 Yes (HRI oseltamivir)
A/Brazil/229/2012 Brazil 20-5-2012 Yes (HRI oseltamivir)
A/Brisbane/35/2013 Australia 9-4-2013 Yes (HRI oseltamivir)
A/Costa Rica/6288/2012 Costa Rica 24-6-2013 Yes (HRI oseltamivir)
A/IIV-Moscow/34/2013 Russian Federation 28-1-2013 Yes (HRI oseltamivir)
A/India/P131027/2013 India 27-1-2013 No
A/Laos/1650/2012 Lao People’s
Democratic Republic
27-8-2012 No
A/Nepal/00854/2012 Nepal 30-9-2012 Yes (HRI oseltamivir)
A/Netherlands/492/2012 The Netherlands 14-8-2012 Yes (HRI oseltamivir)
A/Netherlands/507/2012 The Netherlands 17-8-2012 Yes (HRI oseltamivir)
A/Parana/409/2012 Brazil 22-6-2012 No
A/Pennsylvania/01/2013 United States of
America
18-1-2013 Yes (HRI oseltamivir)
A/Perth/298/2012 Australia 24-12-2012 Yes (HRI oseltamivir)
A/Rio Grande Do Sul/687/2012 Brazil 27-6-2012 No
A/Santa Catarine/229/2012 Brazil 20-5-2012 No
A/St. Petersburg/151/2013 Russian Federation 20-3-2013 Yes (HRI oseltamivir)
A/Tennessee/03/2013 United States of
America
26-3-2013 Yes (HRI oseltamivir)
A/Uppsala/4/2013 Sweden 1-4-2013 No
A/Washington/24/2012 United States of
America
17-6-2012 Yes (HRI oseltamivir)
A/Wyoming/31/2012 United States of
America
26-12-2012 Yes (HRI oseltamivir)
A/Yokosuka/10/2013 Japan 29-1-2013 Yes (HRI oseltamivir)
A/Yokosuka/11/2013 Japan 4-2-2013 Yes (HRI oseltamivir)
a As listed in the table on the WHO website, available at: http://www.who.int/inﬂuenza/gisrs_laboratory/antiviral_susceptibility/nai_overview/en/; accessed 9 May 2014.
b Amino acid position numbering is N1 speciﬁc.
c Percentage based on the number of sequences in the ﬁnal data set after curation – see Supplementary Table 2.
d Yes indicates that the virus was analysed by a WHO CC. HRI = highly reduced inhibition, assessed by in vitro assay for the NAI indicate.
Table 4
Frequency of amino acid substitutions in inﬂuenza NAs, submitted to GISAID and NCBI sequence databases, known to occur clinically but currently of unknown impact, that cause
reduced sensitivity in vitro.a
Type/
Subtype
Neuraminidase amino acid
substitutionb
No. of sequences containing the substitution
(%)c
Virus Included in phenotypic
analysisd
A(N1) D199N 2 (0.2%) A/Kentucky/02/2013 Yes (NI)
A/Paraguay/191/2012 Yes (NI)
I223R 0
N295S 1 (0.1%) A/Salta/1341/2012 Yes (HRI oseltamivir)
A(N2) E119V 4 (0.3%) A/Massachusetts/07/2013 Yes (HRI oseltamivir)
A/Quebec/8118/2013 No
A/Texas/08/2013 Yes (HRI oseltamivir)
A/Victoria/92/2012 Yes (HRI oseltamivir)
R292K 1 (0.1%) A/Kagoshima/2/2012 Yes (HRI oseltamivir/
peramivir)
N294S 0
Be R150K 0
D197E 0
D197N 1 (0.1%) B/South Auckland/8/2012 Yes (NI)
I221T 1 (0.1%)f B/Iowa/05/2013 No
N294S 0
G407S 0
a As listed in the table on the WHO website, available at: http://www.who.int/inﬂuenza/gisrs_laboratory/antiviral_susceptibility/nai_overview/en/; accessed 9 May 2014.
b Amino acid position numbering is A subtype and B type speciﬁc.
c Percentage based on the number of sequences in the ﬁnal data set after curation – see Supplementary Table 2.
d Yes indicates that the virus was analysed by a WHO CC. NI = normal inhibition; HRI = highly reduced inhibition, assessed by in vitro assay for the NAIs indicated.
e The H273Y substitution found in the WHO CC data was not included here, because it did not fulﬁl the requirements for screening: a new substitution should be present in
the clinical specimen and more than a single occurrence if in a patient who has not been treated with a NAI.
f A virus containing an I221N substitution was also present but in phenotypic analyses it showed NI by all NAIs.
A. Meijer et al. / Antiviral Research 110 (2014) 31–41 39sequence containing D197N substitution (Table 4). The viruses
with the D199N substitution showed 2- to 3-fold increases in
oseltamivir IC50, values similar to the 3-fold increase listed in theAVWG table based on a previous study (Ghedin et al., 2011),
however they were below the threshold of RI by deﬁnition. The
inﬂuenza B virus containing the NA D197N substitution showed
40 A. Meijer et al. / Antiviral Research 110 (2014) 31–41only a 2-fold increase in oseltamivir IC50 (therefore classiﬁed as
NI), although in the AVWG table, it is listed that the substitution
confers 4- to 10-fold increases in IC50 based on previous studies
(Mishin et al., 2005; Ison et al., 2006; Hatakeyama et al., 2007;
Sheu et al., 2008). The differences in IC50 fold-change may indicate
that some amino acid substitutions have varying degrees of effect
dependent on additional substitutions that may have occurred in
the NA in the course of virus evolution, i.e. effects may differ
dependent on the NA backbone a particular substitution occurs
in. Two NA sequences identiﬁed in the databases, one with an N2
E119V substitution and the other a B NA I221T substitution
(Table 4), were not among the viruses tested by phenotypic assays
at the WHO CCs.8. Concluding remarks
The WHO-AVWG was able to perform this global analysis on
inﬂuenza antiviral susceptibility thanks to NICs within the WHO
GISRS fulﬁlling their Terms of Reference (ToR) by collecting
inﬂuenza virus positive clinical specimens and sharing a repre-
sentative proportion of them, or viruses recovered, with the
WHO CCs for further detailed characterization (Kitler et al.,
2002). However, the WHO CC data contained low numbers of
viruses from the WHO regions of Africa, South-East Asia and
the Eastern Mediterranean, possibly due to the difﬁculties in set-
ting up surveillance systems and establishing NICs in these
regions. Pooling of IC50 data generated by WHO CCs was possible
using methodology based on IC50 fold-change values, developed
by the WHO-AVWG, and validated as described in this paper.
This methodology could be used to include IC50 data generated
by NICs in pooled analysis if a suitable reporting system was
in place, thereby increasing the coverage and representativeness
to obtain a more robust measure of global inﬂuenza antiviral
susceptibility.
Based on our current analysis, approximately 99% of all viruses
circulating during 2012–2013 were sensitive to all four NAIs and
therefore these drugs remain an appropriate choice for the treat-
ment and prophylaxis of inﬂuenza virus infections. Our data dem-
onstrated that RI and HRI viruses are not circulating at signiﬁcant
levels in the communities providing viruses; however, surveillance
data does not allow signiﬁcant insight about post-treatment RI and
HRI viruses. Plans of the WHO-AVWG to improve the data collec-
tion and analysis include:
1. The use of only the median of NI viruses to calculate the fold-
change values to further standardise data interpretation;
2. Sequencing of the NA of all viruses showing RI or HRI, including
those that are just above the threshold for RI; and
3. Deﬁnition of a minimum critical clinical and epidemiological
dataset to be included with a virus isolate or clinical specimen
submitted to a WHO CC.
The latter will provide an opportunity to include further
information on risk factors for the emergence of viruses with
reduced susceptibility, such as an immunocompromised status
while being treated with NAI, prolonged therapy with NAI, and
prophylaxis. However, a major hurdle in collecting this type of data
that cannot be addressed by the WHO CCs, is the ability of NICs to
obtain this level of information in a timely manner. Importantly,
obtaining this information should not delay submission of viruses
or virus positive clinical specimens to NICs and subsequently to
WHO CCs for virus characterisation in relation to the scheduled
WHO vaccine recommendation meetings in February and
September each year.Contributions
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